Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 78.95M P/E - EPS this Y 30.80% Ern Qtrly Grth -
Income -47.41M Forward P/E -1.94 EPS next Y 17.40% 50D Avg Chg -2.00%
Sales 10.02M PEG - EPS past 5Y - 200D Avg Chg 7.00%
Dividend N/A Price/Book 2.10 EPS next 5Y - 52W High Chg -55.00%
Recommedations 2.20 Quick Ratio 4.37 Shares Outstanding 5.89M 52W Low Chg 69.00%
Insider Own 0.19% ROA -32.46% Shares Float 4.88M Beta 3.76
Inst Own 36.33% ROE -143.19% Shares Shorted/Prior 50.10K/56.04K Price 0.79
Gross Margin -296.17% Profit Margin - Avg. Volume 287,417 Target Price 21.75
Oper. Margin -452.49% Earnings Date May 2 Volume 110,540 Change -2.61%
About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Curis, Inc. News
04/05/24 Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
04/05/24 Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/04/24 Curis to Present at Upcoming Healthcare Conferences in April
02/09/24 Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript
02/08/24 Curis Provides Fourth Quarter 2023 Business Update
02/01/24 Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
12/18/23 Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement
12/12/23 Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
12/11/23 Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
12/06/23 Curis Announces Three Presentations at ASH
12/05/23 Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
11/03/23 Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript
11/03/23 Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year
11/02/23 Curis Provides Third Quarter 2023 Business Update
10/30/23 2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?
10/26/23 Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
10/23/23 We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely
09/22/23 Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
09/12/23 Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer
09/06/23 Curis to Present at Upcoming Healthcare Conferences in September
CRIS Chatroom

User Image NickyTwits Posted - 17 hours ago

$CRIS 4 abstracts at ASCO. https://meetings.asco.org/abstracts-presentations/search?query=*&q=curis&sortBy=Relevancy&filters=%7B%22meetingTypeName%22:%5B%7B%22key%22:%22ASCO%20Annual%20Meeting%22%7D%5D,%22meetingYear%22:%5B%7B%22key%22:2024%7D%5D,%22mediaType%22:%5B%7B%22key%22:%22Abstracts%22%7D%5D%7D

User Image NickyTwits Posted - 1 day ago

$CRIS ASCO abstract titles are out at 10am tomorrow. Stay patient. ๐Ÿœ๏ธ

User Image MaiXin Posted - 1 day ago

$CRIS Buy the dip๐Ÿ’ชโ€ฆnow itโ€˜s time๐Ÿ‘

User Image jasgus Posted - 2 days ago

$CRIS gotta admit nice looking chawt. itz a buy

User Image BigCityCat Posted - 5 days ago

$ICU it's down almost 50% in 2 days. It's over sold. RS could help this stock. Look at $CRIS it had an RS and increased it's value. If there's an RS and the price rises the dollar value of your investment still rises. Could be a time for a starter at this point.

User Image Topzero Posted - 6 days ago

$CRIS Why this stupidity? Isn't there a large company that buys this entire company? The number of shares is very small and stupid people are selling. I swear, if I had $5 million, I would buy the shares and fire the stupid management. The price of each share is supposed to be $70 or more.

User Image MaiXin Posted - 1 week ago

$CRIS https://www.curis.com/wp-content/uploads/2024/04/2024-AACR-Poster_von-Roemeling_Final_Curis_resized.pdf

User Image MaiXin Posted - 1 week ago

$CRIS https://www.curis.com/wp-content/uploads/2024/04/AACR-2024-poster_final.pdf

User Image Topzero Posted - 1 week ago

$CRIS SEC reported Today (15APR2024) that KINGDON CAPITAL MANAGEMENT L L INCREASED $CRIS shares. Before: 284,150 Shares. Now: 345,730 Shares. Newly Added: 61,580 Shares. Increase: 21.67% Approx Trxn Value: $922.4K Own %: 5.90% ๐Ÿ”ฅ๐Ÿ”ฅ๐Ÿ”ฅ๐Ÿ”ฅ๐Ÿ”ฅ

User Image Topzero Posted - 1 week ago

$CRIS SEC reported Today (15APR2024) that KINGDON CAPITAL MANAGEMENT L L INCREASED $CRIS shares. Before: 284,150 Shares. Now: 345,730 Shares. Newly Added: 61,580 Shares. Increase: 21.67% Approx Trxn Value: $922.4K Own %: 5.90% ๐Ÿ”ฅ๐Ÿ”ฅ๐Ÿ”ฅ๐Ÿ”ฅ๐Ÿ”ฅ

User Image NickyTwits Posted - 1 week ago

$CRIS Kingdon Capital added another ~60k shares (now at ~346k total). 5.9% ownership of the company. ๐Ÿœ๏ธ

User Image UCD_12dd Posted - 1 week ago

$CRIS 8% drop this morning? Why?

User Image NickyTwits Posted - 1 week ago

$CRIS "Maybe a little bit of a leap of imagination here. You probably are well aware of this but Multiple Sclerosis (MS). Right? Brain penetrance is a big deal in MS as being the failure for KTA, this, that and the other. Its interesting" Dentzer: "Ya and as you can imagine given my past advision, that is a forefront of my thinking as well. IRAK4 as a target looks to be very important in many different spaces. As of right now our published focus is going to be in Leukemia and Lymphoma, but there are a number of areas that we are going to be perusing that we see where this makes sense. Obviously MS is one of those.... hot on the heals [of year end] were going to expand everywhere we can with this opportunity." They are gearing up to blow the top off. Will need a partner to do so. Stay patient. ๐Ÿœ๏ธ

User Image MaiXin Posted - 1 week ago

$CRIS In Curis we trust๐Ÿ’ช

User Image fda_tracker Posted - 1 week ago

$CRIS Phase 2 trial w/est Apr completion date NCT05178342: https://www.clinicaltrials.gov/study/NCT05178342 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image DJHILL96 Posted - 2 weeks ago

$CRIS https://bloodcancerstoday.com/post/claudio-cerchione-md-phd-shares-promising-data-on-emavusertib-in-aml

User Image MaiXin Posted - 2 weeks ago

$CRIS This is not a one trick ponyโ€ฆ.๐Ÿ’ช๐Ÿ’ช

User Image MaiXin Posted - 2 weeks ago

$CRIS

User Image NickyTwits Posted - 2 weeks ago

$CRIS healthy backtest. Should see the next move to low 20s towards the tail end of this month. ๐Ÿœ๏ธ -ASCO Abstract Titles April 24 -Merck trial starting in April -LUCAS trial primary completion in April -Pancreatic trial updated today. 9 months in. Closing in on 1 year to completion. 25 sites.

User Image swiss24 Posted - 2 weeks ago

$CRIS buyout ? Which price?

User Image NickyTwits Posted - 2 weeks ago

$CRIS Hands down the best presentation I have heard Dentzer give. Great responses to tough questions at the end. Must give credit where it is due. ๐Ÿœ๏ธ

User Image MaiXin Posted - 2 weeks ago

$CRIS

User Image brian_AR Posted - 2 weeks ago

$CRIS my target on this one is $200

User Image Covo84 Posted - 2 weeks ago

$CRIS what do you expect for tomorrow?

User Image MaiXin Posted - 2 weeks ago

$CRIS New Corporate presentation available๐Ÿ˜€๐Ÿ‘๐Ÿปโ€ฆNew Market opportunities are listed based on current development programs. https://www.curis.com/wp-content/uploads/2024/04/2024-04-Corporate-Presentation.pdf

User Image NickyTwits Posted - 2 weeks ago

$CRIS new corporate deck ๐Ÿ˜ฎโ€๐Ÿ’จ https://www.curis.com/wp-content/uploads/2024/04/2024-04-Corporate-Presentation.pdf

User Image NickyTwits Posted - 2 weeks ago

$CRIS Heres the abstract text. AACR doesnt allow inclusion of results in these abstracts. We will see what Dentzer has to say/expand on come Monday. https://www.abstractsonline.com/pp8/#!/20272/presentation/11617

User Image Yodalay Posted - 2 weeks ago

$CRIS "Curis approved the grant of inducement stock options to purchase a total of 8,550 shares of Curis common stock to a new employee" Who is the new Employee?

User Image NickyTwits Posted - 2 weeks ago

$CRIS quick reminder for longs to not expect much data today from the abstract. Curis has said to not expect data until 2H 2024 for this trial. Main items we are looking for is that it is proving to be well tolerated/safe, and any hint of efficacy is a bonus. This study is fontline. Intended for AML all comers and has huge impacts on the targetable market for the drug. Stay focused ๐Ÿœ๏ธ

User Image Stock_Titan Posted - 2 weeks ago

$CRIS Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.stocktitan.net/news/CRIS/curis-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-uv2fgvqru7js.html

Analyst Ratings
HC Wainwright & Co. Buy Feb 9, 24
Truist Securities Buy Nov 17, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dentzer James E President & CEO President & CEO Jan 27 Sell 3.13 5,500 17,215 64,877 01/31/22
Dentzer James E President & CEO President & CEO Jan 26 Sell 10.77 5,377 57,910 67,268 01/26/21